• 2. November 2024

InDex Pharmaceuticals receives grant from Sweden´s innovation agency Vinnova for pre-clinical development of DIMS compounds in inflammation

ByInDex Pharmaceuticals

Mai 23, 2016

Teile den Beitrag mit Freunden